# US 2010/0137561 A1 · Process for preparing therapeutic peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137561 A1
- Document ID: US20100137561A1
- Status: Published application
- Kind: A1
- Application number: 12/630,002
- Filed: 2009-12-03
- Published: 2010-06-03
- Earliest claimed: 2008-12-03
- Inventors: Lin Chen
- Web page: https://patentgrep.com/patent/US20100137561A1

## CPC

- C07K 14/64: Relaxins
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application discloses processes for synthesizing human relaxin Chain B for treatment of diseases mediated by relaxin. This application in particular discloses processes of synthesizing the Chain B of human relaxin using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to couple the fragments.

## Claims

### Claim 1

A process for preparing a relaxin Chain B peptide comprising the step of:
a) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 3)
Z-Met-Ser-Thr-Trp-OH
wherein:
Z is H—; and
one or more residues of said sequence optionally include side chain protection.

### Claim 2 (depends on 1)

The process of claim 1, further comprising the steps of:
b) coupling the peptide fragment of step a) in solution to H-Ser-OtBu in order to provide a peptide fragment including the amino acid sequence of
(SEQ ID NO. 4)
Z-Met-Ser-Thr-Trp-Ser-OtBu
wherein:
Z is N-terminal protecting group Fmoc-; and
one or more residues of said sequence optionally include side chain protection; and
c) removing the N-terminal protecting group to afford a peptide fragment including the amino acid sequence of
(SEQ ID NO. 4)
Z-Met-Ser-Thr-Trp-Ser-OtBu
wherein:
Z is H; and
one or more residues of said sequence optionally include side chain protection.

### Claim 3 (depends on 2)

The process of claim 2, further comprising the steps of:
d) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 2)
Z-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
OH
wherein:
Z is N-terminal protecting group Fmoc-; and
one or more residues of said sequence optionally include side chain protection;
e) coupling the peptide fragment of step d) in solution to the peptide fragment of step c) in the presence of an alkali metal halide in order to provide a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
Met-Ser-Thr-Trp-Ser-OtBu
wherein:
Z is N-terminal protecting group Fmoc-; and
one or more residues of said sequence optionally include side chain protection; and
f) removing the N-terminal protecting group to afford a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
Met-Ser-Thr-Trp-Ser-OtBu
wherein:
Z is H; and
one or more residues of said sequence optionally include side chain protection.

### Claim 4 (depends on 3)

The process of claim 3, further comprising the steps of:
g) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 1)
Z-Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-
OH
wherein:
Z is N-terminal protecting group Boc-; and
one or more residues of said sequence optionally include side chain protection; and
h) coupling the peptide fragment of step f) in solution to the peptide fragment of step g) in the presence of an alkali metal halide in order to provide a peptide including the amino acid sequence of
(SEQ ID NO. 6)
Z-Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-
Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
Met-Ser-Thr-Trp-Ser-OtBu
wherein:
Z is N-terminal protecting group Boc-; and
one or more residues of said sequence optionally include side chain protection.

### Claim 5 (depends on 4)

The process of claim 4, further comprising the step of:
i) contacting the peptide resulting from step h) with acid in order to remove the N-terminal protecting group and deprotect the amino acid side chains to afford the deprotected relaxin Chain B amino acid sequence of
(SEQ ID NO. 7)
Z-Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-
Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
Met-Ser-Thr-Trp-Ser-OH
wherein:
Z is H.

### Claim 6

A process for preparing a relaxin Chain B peptide comprising the step of:
a) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 3)
Z-Met-Ser(OtBu)-Thr(OtBu)-Trp-OH
wherein:
Z is N-terminal protecting group Fmoc-.

### Claim 7 (depends on 6)

The process of claim 6, further comprising the step of:
b) coupling the peptide fragment of step a) in solution to H-Ser(tBu)-OtBu in order to provide a peptide fragment including the amino acid sequence of
(SEQ ID NO. 4)
Z-Met-Ser(OtBu)-Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is N-terminal protecting group Fmoc-.

### Claim 8 (depends on 7)

The process of claim 7, further comprising the steps of:
c) removing the N-terminal protecting group to afford a peptide fragment including the amino acid sequence of
(SEQ ID NO. 4)
Z-Met-Ser(OtBu)-Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H;
d) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 2)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln
(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-OH
wherein:
Z is N-terminal protecting group Fmoc-; and
e) coupling the peptide fragment of step c) in solution to the fragment of step d) in the presence of an alkali metal halide in order to provide a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln
(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-Thr
(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is N-terminal protecting group Fmoc-; and
f) removing the N-terminal protecting group to afford a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln
(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-Thr
(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H.

### Claim 9 (depends on 8)

The process of claim 8, further comprising the steps of:
g) introducing a peptide fragment including the amino acid sequence of
(SEQ. ID NO. 1)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-Glu
(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-OH
wherein:
Z is N-terminal protecting group Boc-;
h) coupling the peptide fragment of step f) in solution to the peptide fragment of step g) in the presence of an alkali metal halide in order to provide a peptide including the amino acid sequence of
(SEQ ID NO. 6)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-Glu
(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-Arg(Pbf)-
Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln(Trt)-Ile-Ala-
Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-Thr(OtBu)-Trp-Ser
(OtBu)-OtBu
wherein:
Z is N-terminal protecting group Boc-;
i) contacting the peptide resulting from step h) with acid in order to remove the N-terminal protecting group and deprotect the amino acid side chains to afford the deprotected relaxin Chain B amino acid sequence of
(SEQ ID NO. 7)
Z-Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-
Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-
Met-Ser-Thr-Trn-Ser-OH
wherein:
Z is H.

### Claim 10

A process for preparing a relaxin Chain B peptide comprising the step of:
a) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 2)
Fmoc-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-OH
wherein:
Z is N-terminal protecting group Fmoc-;
b) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 4)
H-Met-Ser(OtBu)-Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H;
c) coupling the peptide fragment of step a) in solution to the fragment of step b) in the presence of an alkali metal halide in order to provide a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-
Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is N-terminal protecting group Fmoc-;
d) removing the N-terminal protecting group to afford a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-
Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H.

### Claim 11

A process for preparing a relaxin Chain B peptide comprising the step of:
a) introducing a peptide fragment including the amino acid sequence of
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-
Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H;
b) introducing a peptide fragment including the amino acid sequence of
(SEQ. ID NO. 1)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-
Glu(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-OH
wherein:
Z is N-terminal protecting group Boc-;
c) coupling the peptide fragment of step a) in solution to the peptide fragment of step b) in the presence of an alkali metal halide in order to provide a peptide including the amino acid sequence of
(SEQ ID NO. 6)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-
Glu(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-
Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln(Trt)-
Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-Thr(OtBu)-
Trp-Ser(OtBu)-OtBu
wherein:
Z is N-terminal protecting group Boc.

### Claim 12

A peptide of the amino acid sequence
(SEQ. ID NO. 1)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-
Glu(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-OH
wherein:
Z is H or N-terminal protecting group Boc.

### Claim 13

A peptide of the amino acid sequence
(SEQ. ID NO. 2)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-OH
wherein:
Z is H or N-terminal protecting group Fmoc.

### Claim 14

A peptide of the amino acid sequence
(SEQ. ID NO. 3)
Z-Met-Ser(OtBu)-Thr(OtBu)-Trp-OH
wherein:
Z is H or N-terminal protecting group Fmoc.

### Claim 15 (depends on 4)

A peptide prepared by the process of claim 4 comprising the amino acid sequence
(SEQ ID NO. 4)
Z-Met-Ser(OtBu)-Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H or N-terminal protecting group Fmoc.

### Claim 16

A peptide of the amino acid sequence
(SEQ ID NO. 5)
Z-Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-
Gln(Trt)-Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-
Thr(OtBu)-Trp-Ser(OtBu)-OtBu
wherein:
Z is H or N-terminal protecting group Fmoc.

### Claim 17

A peptide of the amino acid sequence
(SEQ. ID NO. 6)
Z-Asp(OtBu)-Ser(tBu)-Trp(Boc)-Met-Glu(OtBu)-
Glu(OtBu)-Val-Ile-Lys(Boc)-Leu-Cys(Trt)-Gly-
Arg(Pbf)-Glu(OtBu)-Leu-Val-Arg(Pbf)-Ala-Gln(Trt)-
Ile-Ala-Ile-Cys(Trt)-Gly-Met-Ser(OtBu)-Thr(OtBu)-
Trp-Ser(OtBu)-OtBu
wherein:
Z is H or N-terminal protecting group Boc or Fmoc.
